BioWare's scientific strategies are to focus mainly in the BioTech areas that are presently underdeveloped both in Taiwan and throughout the rest of the world. The reconstitution category from present technologies is the most developed and has the least amount of space for newcomers. In contrast, the remaining areas of scientific activity, such as exploration and daily use, would receive the lion's share of BioWare's attention, with the daily use category being BioWare's number one priority.
In order to establish a competitive capability for long-term projects, focusing on exploring those novel new applications for our cloned genes and the medical tool that have very huge market size in the future, BioWare is also obligate to develop short-term projects which can be commercialized within one to two years.
